<DOC>
	<DOC>NCT02157012</DOC>
	<brief_summary>To examine the safety and effectiveness after Xeljanz treatment in rheumatoid arthritis patients</brief_summary>
	<brief_title>Evaluation of the Condition of Rheumatoid Arthritis After Treatment</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Rheumatoid arthritis Other connective tissue disease</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>